Skip to Main Content

Selected Publications – Sorted by Cancer Type

Names of COPPER members appear in bold


Richman IB, Long JB, Hoag JR, Upneja A, Hooley R, Xu X, Kunst N, Aminawung JA, Kyanko KA, Busch SH, Gross CP. Comparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening among Women 40-64 Years Old. J Natl Cancer Inst. 2021;113(11):1515-1522. PMID33822120.

Gupta A, Jhawar SR, Sayan M, Yehia ZA, Haffty BG, Yu JB, Wang SY. Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. J Clin Oncol. 2021;39(21):2386–2396. PMID32211582.

Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Res. 2021;23(1):14. PMID33514405.

Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Lindau ST, Richman IB, Gross CP. Understanding Regional Variation in the Cost of Breast Cancer Screening Among Privately Insured Women in the United States. Med Care. 2021;59(5):437-443. PMID33560712.

Xu X, Soulos PR, Herrin J, Wang SY, Pollack CE, Evans SB, Yu JB, Gross CP. Physician trajectories of abandoning long-course breast radiotherapy and their cost impact. Health Serv Res. 2021;56(3):497-506. PMID33070305.

Potnis KC, Gross CP, Richman IB. Industry Payments and New Breast Cancer Screening Technology Use. J Gen Intern Med. 2021;36(5):1440-1442. PMID32468434.

Djulbegovic M, Aminawung J, Hoag JR, Kyanko KA, Xu X, Busch SH, Gross CP. Current Attitudes and Practices Around Screening Mammography Among Women in the United States: Results of a National Survey. J Gen Intern Med. 2021;36(6):1802-1804. PMID32542502.

Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer. JAMA Netw Open. 2020; 3(11):e2027074. PMID33226431.

Schulman-Green D, Cherlin E, Capasso R, Mougalian SS, Wang SY, Gross CP, Bajaj PS, Eakle K, Patel S, Douglas K, Adelson K. Patient and Family Caregiver Considerations When Selecting Early Breast Cancer Treatment: Implications for Clinical Pathway Development. Patient. 2020;13(6):683-697. PMID32508006.

Aminawung JA, Hoag JR, Kyanko KA, Xu X, Richman IB, Busch SH, Gross CP. Breast cancer supplemental screening: Women's knowledge and utilization in the era of dense breast legislation. Cancer Med. 2020;9(15):5662-5671. PMID32537899.

Kyanko KA, Hoag J, Busch SH, Aminawung JA, Xu X, Richman IB, Gross CP. Dense Breast Notification Laws, Education, and Women's Awareness and Knowledge of Breast Density: a Nationally Representative Survey. J Gen Intern Med. 2020;35(7):1940-1945. PMID31916210.

Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Richman IB, Gross CP. Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance. JAMA Intern Med. 2020;180(5):799-801. PMID32202606.

Wang SY, Abujarad F, Chen T, Evans SB, Killelea BK, Mougalian SS, Fraenkel L, Gross C. "Radiotherapy for older women (ROW)": A risk calculator for women with early-stage breast cancer. J Geriatr Oncol. 2020;11(5):850-859. PMID31899199.

Yu JB, Pollack CE, Herrin J, Soulos PR, Zhu W, Xu X, Gross CP. Peer influence on physician use of shorter course external beam radiation therapy for patients with breast cancer. Pract Radiat Oncol. 2020;10(2):75-83. PMID31785370.

Killelea BK, Herrin J, Soulos PR, Pollack CE, Forman HP, Yu J, Xu X, Tannenbaum S, Wang SY, Gross CP. Income disparities in needle biopsy patients prior to breast cancer surgery across physician peer groups. Breast Cancer. 2020;27(3):381-388. PMID31792804.

Killelea BK, Evans SB, Mougalian SS, Gross CP, Fraenkel L, Wang SY. Association between perceived benefits and receipt of radiotherapy among older breast cancer patients. Breast J. 2020;26(2):231-234. PMID31478585.

Hung P, Wang SY, Killelea BK, Mougalian SM, Evans SB, Sedghi T, Gross CP. Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ. JNCI Cancer Spectr. 2019;3(4):pkz052.

Richman IB, Hoag JR, Xu X, Forman HP, Hooley R, Busch SH, Gross CP. Adoption of Digital Breast Tomosynthesis in Clinical Practice. JAMA Intern Med. 2019;179(7):1292-1295. PMID31233086.

Mougalian SS, Aminawung JA, Presley CJ, Canavan ME, Holland ML, Hu X, Gross CP. Prioritization of Patient-Reported Outcomes by Women With Metastatic Breast Cancer. JCO Clin Cancer Inform. 2019;(3):1-3. PMID30730764.

Pariser AC, Sedghi T, Soulos PR, Killelea B, Gross CP, Mougalian SS. Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States. Breast Cancer Res Treat. 2019;178(2):419-426. PMID31401686.

Yu JB, Pollack CE, Herrin J, Zhu W, Soulos PR, Xu X, Gross CP. Persistent use of extended fractionation palliative radiotherapy for Medicare beneficiaries with metastatic breast cancer, 2011-2014. Am J Clin Oncol. 2019;42(6):493-499. PMID31033511.

Shi Y, Pollack CE, Soulos PR, Herrin J, Christakis NA, Xu X, Gross CP. Association between Degrees of Separation in Physician Networks and Surgeons’ Use of Perioperative Breast Magnetic Resonance Imaging. Med Care. 2019;57(6):460-467. PMID31008899.

Busch SH, Hoag JR, Aminawung JA, Xu X, Richman IB, Soulos PR, Kyanko KA, Gross CP. Association of State Dense Breast Notification Laws With Supplemental Testing and Cancer Detection After Screening Mammography. Am J Public Health. 2019;109(5):762-767. PMID30896987.

Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Res Treat. 2019;173(1):209-216. PMID30242577.

Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis. J Natl Compr Canc Netw. 2019 Jan;17(1):39-46. PMID30659128.

Tannenbaum SS, Soulos PR, Herrin J, Pollack CE, Xu X, Christakis NA, Forman HP, Yu JB, Killelea BK, Wang SY, Gross CP. Surgeon Peer Network Characteristics and Adoption of New Imaging Techniques in Breast Cancer: A Study of Perioperative MRI. Cancer Med. 2018;7(12):5901-5909. PMID30444005.

Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, Silber AL, Davidoff AJ, Sedghi T, Gross CP. Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat. 2018;172(2):453-461. PMID30099634.

Bachand J, Soulos PR, Herrin J, Pollack CE, Xu X, Ma X, Gross CP. Physician peer group characteristics and timeliness of breast cancer surgery. Breast Cancer Res Treat. 2018;170(3):657-665. PMID29693229.

Wang SY, Dang W, Richman I, Mougalian SS, Evans SB, Gross CP. Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal. J Clin Oncol. 2018;36(16):1619-1627. PMID29659329.

Hong JC, Rahimy E, Gross CP, Shafman T, Hu X, Yu JB, Ross R, Finkelstein SE, Dosoretz A, Park HS, Soulos PR, Evans SB. Radiation dose and cardiac risk in breast cancer treatment: An analysis of modern radiation therapy including community settings. Pract Radiat Oncol. 2018;8(3):e79-e86. PMID28888675.

Killelea BK, Long JB, Dang W, Mougalian SS, Evans SB, Gross CP, Wang SY. Associations Between Sentinel Lymph Node Biopsy and Complications for Patients with Ductal Carcinoma In Situ. Ann Surg Oncol. 2018;25(6):1521-1529. PMID29516364.

Avraham T, Gross CP, Killelea BK. Connections Between Hospital Financial Distress, Physician Incentive, and Patient Access to Breast Reconstruction. JAMA Surg. 2018;153(4):351-352. PMID29214317.

Layne TM, Aminawung JA, Soulos PR, Nunez-Smith M, Nunez MA, Jones BA, Wang KH, Gross CP. Quality Of Breast Cancer Care In The US Territories: Insights From Medicare. Health Aff. 2018;37(3):421-428. PMID29505365.

Kelly G, Wang SY, Lucas G, Fraenkel L, Gross CP. Facilitating Meaningful Engagement on Community Advisory Committees in Patient-Centered Outcome Research. Prog Community Health Partnersh. 2017;11(3):243-251. PMID29056616.

Tannenbaum S, Soulos PR, Herrin J, Mougalian S, Long JB, Wang R, Ma X, Gross CP, Xu X. Regional Medicare Expenditures and Survival Among Older Women With Localized Breast Cancer. Med Care. 2017; 55(12):1030-1038; PMID29068906.

Rahimy E, Hong JC, Gross CP, Hu X, Soulos PR, Shafman T, Connor HJ, Ross R, Yu JB, Dosoretz A, Evans SB. Increased Number of Beam Angles Is Associated With Higher Cardiac Dose in Adjuvant Fixed Gantry Intensity Modulated Radiation Therapy of Left-Sided Breast Cancer. Int J Radiat Oncol Biol Phys. 2017; 99(5):1137-1145; PMID28864402.

Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ. Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PLoS One. 2017;12(9):e0184747. PMID28902882.

Lannin DR, Wang S. Are Small Breast Cancers Good because They Are Small or Small because They Are Good? N Engl J Med. 2017;376(23):2286-91. PMID28591529.

Pollack CE, Soulos PR, Herrin J, Xu X, Christakis NA, Forman HP, Yu JB, Killelea BK, Wang SY, Gross CP. The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer. J Natl Cancer Inst. 2017;109(8). PMID28376191.

Stratton J, Hu X, Soulos PR, Davidoff AJ, Pusztai L, Gross CP, and Mougalian SS. Bone density screening in postmenopausal women with early stage breast cancer on aromatase inhibitors. J Oncol Pract. 2017;13(5):e505-e515 . PMID28267392.

Davis BA, Aminawung JA, Abu-Khalaf MM, Evans SB, Su K, Mehta R, Wang SY, Gross CP. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study. J Natl Compr Canc Netw. 2017;15(3):346-354. PMID28275035.

Wang EH, Park HS, Rutter CE, Gross C, Soulos PR, Yu JB, Evans SB. Association between Access to Accelerated Partial Breast Irradiation and Utilization of Adjuvant Radiation Therapy. Cancer. 2017;123(3):502-511. PMID27657353.

Yeboa DN, Xu X, Jones BA, Soulos P, Gross C, Yu JB. Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004-2009. Am J Clin Oncol. 2016;39(6):568-574. PMID24879475.

Yeboa DN, Evans SB. Contemporary Breast Radiotherapy and Cardiac Toxicity. Semin Radiat Oncol. 2016;26(1):71-8. PMID26617212.

Lester-Coll NH, Rutter CE, Evans SB. Cost-effectiveness assessment of lumpectomy cavity boost in elderly women with early stage estrogen receptor positive breast cancer receiving adjuvant radiotherapy. Radiother Oncol. 2016;119(1):52-6. PMID26867968.

Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, Silber A, Gross CP. Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ. Breast Cancer Res Treat. 2016;158(1):139-48. PMID27287780.

Howard DH, Soulos PR, Chagpar AB, Mougalian S, Killelea B, Gross CP. Contrary To Conventional Wisdom, Physicians Abandoned A Breast Cancer Treatment After A Trial Concluded It Was Ineffective. Health Aff. 2016;35(7):1309-15. PMID27385249.

Su KW, Hall J, Soulos PR, Abu-Khalaf MM, Evans SB, Mougalian SS, Rutter CE, Davidoff AJ, Gross CP. Association of 21-Gene Recurrence Score Assay and Adjuvant Chemotherapy Use in the Medicare Population, 2008-2011. J Geriatr Oncol. 2016;7(1):15-23. PMID26704661.

Rutter CE, Yao X, Mancini BR, Aminawung JA, Chagpar AB, Saglam O, Hofstatter EW, Abu-Khalaf M, Gross CP, Evans SB. Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer. Clin Breast Cancer. 2016;16(1):59-62. PMID26483315.

Wang SY, Long JB, Killelea BK, Evans SB, Roberts KB, Silber A, Gross CP. Preoperative Breast Magnetic Resonance Imaging and Contralateral Breast Cancer Occurrence Among Older Women With Breast Cancer. J Clin Oncol. 2016;34(4):321-8. PMID26628465.

Xu X, Herrin J, Soulos PR, Saraf A, Roberts KB, Killelea BK, Wang SY, Long JB, Wang R, Ma X, Gross CP. The Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer. Health Serv Res. 2016;51(1):167-86. PMID26119176.

Killelea BK, Yang VQ, Wang SY, Hayse B, Mougalian S, Horowitz NR, Chagpar AB, Pusztai L, Lannin DR. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Database. J Clin Oncol. 2015;33(36):4267-76. PMID26598753.

Evans SB, Yu JB. Hypofractionated radiation therapy versus conventionally fractionated radiation therapy for early-stage breast cancer: how do we choose? Future Oncol. 2015;11(15):2105-7. PMID26235175.

Mougalian SS, Soulos PR, Killelea BK, Lannin DR, Abu-Khalaf M, DiGiovanna M, Sanft T, Pusztai L, Gross CP, Chagpar AB. Use of Neoadjuvant Chemotherapy for Stage I-III Breast Cancer in the United States. Cancer. 2015;121(15)2544-52. PMID25902916.

Pollack CE, Soulos PR, Gross CP. Physician’s Peer Exposure and the Adoption of a New Cancer Treatment Modality. Cancer. 2015;121(16):2799-807. PMID25903304.

Rutter CE, Lester-Coll NG, Mancini BR, Corso CD, Park HS, Yeboa DN, Gross CP, Evans SB. The evolving role of adjuvant radiotherapy for elderly women with early-stage breast cancer. Cancer. 2015;121(14):2331-40. PMID25810128.

Feinstein AJ, Long JB, Soulos PR, Ma X, Herrin J, Frick KD, Chagpar AB, Krumholz HM, Yu JB, Ross JS, Gross CP. Older Women with Localized Breast Cancer: Costs and Survival Rates Increased across Two Time Periods. Health Aff. 2015;34(4):592-600. PMID25847641.

Wang EH, Mougalian SS, Soulos PR, Smith BD, Haffty BG, Gross CP, Yu JB. Adoption of Intensity Modulated Radiation Therapy For Early-Stage Breast Cancer From 2004 Through 2011. Int J Radiat Oncol Biol Phys. 2015;91(2):303-11. PMID25442334.

Killelea BK, Long JB, Chagpar AB, Ma X, Wang R, Ross JS, Gross CP. Evolution of breast cancer screening in the Medicare population: Clinical and economic implications. J Natl Cancer Inst. 2014;106(8). PMID25031307.

Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, Yu JB, Evans SB, Chagpar AB, Gross CP. Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer. J Natl Cancer Inst. 2014;106(3):dju008. PMID24598714.

Elmore JG, Gross CP. The Cost of Breast Cancer Screening in the United States: A Picture Is Worth... a Billion Dollars? Ann Intern Med. 2014;160(3):203-204-204.

Gross CP, Long JB, Ross JS, Abu-Khalaf M, Wang R, Killelea BK, Gold HT, Chagpar AB, Ma X. The Cost of Breast Cancer Screening in the Medicare Population. JAMA Intern Med. 2013;173(3):220-6. PMID23303200.

Presley CJ, Soulos PR, Herrin J, Roberts KB, Yu JB, Killelea B, Lesnikoski B, Long JB, Gross CP. Patterns of use and short-term complications of breast brachytherapy in the national Medicare population in 2008-2009. J Clin Oncol. 2012;30(35):4302-7. PMID23091103.

Soulos PR, Yu JB, Roberts KB, Raldow AC, Herrin J, Long JB, Gross CP. Assessing the impact of a cooperative group trial on breast cancer care in the Medicare population. J Clin Oncol. 2012;30(14):1601-7. PMID22393088.

Fox JP, Zikmund-Fisher BJ, Gross CP. Older patient experiences in the mammography decision-making process. Arch Int Med. 2012;172(1):62-4. PMID22232149.


Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Netw Open. 2021;4(10): e2128646. PMID34623406.

Leapman MS, Wang R, Ma S, Gross CP, Ma X. Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer. JAMA Oncol. 2021;7(1):52-58. PMID33237277.

Ghabili K, Park HS, Yu JB, Sprenkle PC, Kim SP, Nguyen KA, Ma X, Gross CP, Leapman MS. National trends in the management of patients with positive surgical margins at radical prostatectomy. World J Urol. 2021;39(4):1141-1151. PMID32562045.

Yang DX, Makarov DV, Gross CP, Yu JB. Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening. Cancer Control. 2020;27(1):1073274820902267. PMID32003227.

Yang DX, Verma V, An Y, Yu JB, Sprenkle PC, Leapman MS, Park HS. Radiation Dose to the Rectum With Definitive Radiation Therapy and Hydrogel Spacer Versus Postprostatectomy Radiation Therapy. Adv Radiat Oncol. 2020;5(6):1225-1231. PMID33305083.

Kim SP, Tilburt JC, Shah ND, Yu JB, Konety B, Nguyen PL, Abouassaly R, Williams SB, Gross CP. A National Survey of Radiation Oncologists and Urologists on Perceived Attitudes and Recommendations of Active Surveillance for Low-Risk Prostate Cancer. Clin Genitourin Cancer. 2019;17(3):e472-e481. PMID30827923.

Kim SP, Shah ND, Meropol NJ, Tilburt JC, Nguyen PL, Yu JB, Abouassaly R, Kim A, Gross CP. Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Eur Urol Oncol. 2019;2(2):189-195. PMID31017095.

Kim SP, Gross CP, Shah ND, Tilburt JC, Konety B, Williams SB, Weight CJ, Yu JB, Kumar AMS, Meropol NJ. Perceptions of Barriers Towards Active Surveillance for Low-Risk Prostate Cancer: Results From a National Survey of Radiation Oncologists and Urologists. Ann Surg Oncol. 2019;26(2):660-668. PMID30311161.

Leapman MS, Wang R, Park HS, Yu JB, Weinreb JC, Gross CP, Ma X. Association Between Prostate Magnetic Resonance Imaging and Observation for Low-Risk Prostate Cancer. Urology. 2019;124:98-106. PMID30107188.

Mahal AR, Mahal BA, Nguyen PL, Yu JB. Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer. 2018; 124(4):752-759; PMID29084350.

Yu JB, Hamstra D. Point: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Oncology. 2017;31(11):830-2. PMID29179251.

Yu JB. Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales. J Clin Oncol. 2017;35(17):1867-1869. PMID28355114.

Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, and Yu JB. Patient-reported quality of life after stereotactic body radiation therapy vs. moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol. 2016;121(2)294-298. PMID27890426.

Kim SP, Karnes RJ, Gross CP, Meropol NJ, Van Houten H, Abouassaly R, Shah ND. Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States. Urology. 2016;97:111-117. PMID27527411.

Lester-Coll NH, Johnson S, Magnuson WJ, Goldhaber SZ, Sher DJ, D'Amico AV, Yu JB. Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. J Natl Cancer Inst. 2016;109(6). PMID28040795.

Lester-Coll NH, Park HS, Rutter CE, Corso CD, Mancini BR, Yeboa DN, Kim SP, Gross CP, Yu JB. The Association between Evaluation at Academic Centers and the Likelihood of Expectant Management in Low-Risk Prostate Cancer. Urology. 2016;96:128-135. PMID27392652.

Wang EH, Gross CP, Tilburt JC, Yu JB, Nguyen PL, Smaldone MC, Shah ND, Abouassally R, Sun M, Kim SP. Shared decision making and use of decision AIDS for localized prostate cancer: perceptions from radiation oncologists and urologists. JAMA Intern Med. 2015;175(5):792-9. PMID25751604.

Wang EH, Yu JB, Gross CP, Abouassaly R, Cherullo EE, Smaldone MC, Shah ND, Kiechle J, Trinh QD, Sun M, Kim SP. Association between surgeon and hospital characteristics and lymph node counts from radical prostatectomy and pelvic lymph node dissection. Urology. 2015;85(4)890-5. PMID25817114.

Makarov DV, Sen S, Soulos PR, Gold HT, Yu JB, Ross J, Gross CP. Regional-level inappropriate imaging rates for prostate and breast cancers are correlated: Potential Implications for Choosing Wisely. JAMA Oncol. 2015;1(2):185-194. PMID26181021.

Yu JB, Sandler HM. Stereotactic body radiation therapy: Let's not give up on progress. Pract Radiat Oncol. 2015;5(3):193-6. PMID25413388.

Wang EH, Yu JB, Gross CP, Smaldone MC, Shah ND, Trinh QD, Nguyen PL, Sun M, Han LC, Kim SP. Variation in Pelvic Lymph Node Dissection among Patients Undergoing Radical Prostatectomy by Hospital Characteristics and Surgical Approach: Results from the National Cancer Database. J Urol. 2015;193(3):820-5. PMID25242393.

Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP. Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of Toxicity. J Clin Oncol. 2014;32(12)1195-201. PMID24616315.

Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, Gross CP. Proton versus intensity-modulated radiotherapy for prostate cancer: Patterns of care and early toxicity. J Natl Cancer Inst. 2013;105(1):25-32. PMID23243199.

Raldow AC, Presley CJ, Yu JB, Sharma R, Cramer LD, Soulos PR, Long JB, Makarov DV, Gross CP. The relationship between clinical benefit and receipt of curative therapy for prostate cancer. Arch Intern Med. 2012;172(4):362-3. PMID22371925.

Ross JS, Wang R, Long JB, Gross CP, Ma X. Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries. Arch Intern Med. 2012;172(2):1601-3. PMID22987029.


Yang SC, Wang JD, Wang SY. Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data. Sci Rep. 2021;11(1):12180. PMID34108586.

Walters SL, Canavan ME, Salazar MC, Resio BJ, Blasberg JD, Mase V, Boffa DJ. A National Study of Surgically-Managed Atypical Pulmonary Carcinoid Tumors. Ann Thorac Surg. 2021;112(3):921-927. PMID33159862.

Jairam V, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH. Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques. Lung Cancer. 2021;161:171-179. PMID34607209.

Yang SC, Gross CP, Wang JD, Wang SY. Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008-2016. J Gen Intern Med. 2021;36(11):3589–3591. PMID33469753.

Salazar MC, Canavan ME, Walters SL, Chilakamarry S, Ermer T, Blasberg JD, Yu JB, Gross CP, Boffa DJ. The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases. JTO Clin Res Rep. 2021;2(3):100143. PMID34590002.

Li AX, Resio BJ, Canavan ME, Papageorge M., Boffa DJ, Blasberg JD. Outcomes of surgically managed primary lung sarcomas: a National Cancer Database analysis. J Thorac Dis. 2021;13(6):3409–3419. PMID34277037.

Davidoff AJ, Canavan ME, Prsic E, Saphire M, Wang SY, Presley CJ. End-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis. Support Care Cancer. 2021;29(7):3921-3932. PMID33389087.

Presley CJ, Han L, O'Leary JR, Zhu W, Corneau E, Chao H, Shamas T, Rose M, Lorenz K, Levy CR, Mor V, Gross CP. Concurrent Hospice Care and Cancer-Directed Treatment for Advanced Lung Cancer and Receipt of Aggressive Care at the End of Life in the Veteran's Health Administration. J Palliat Med. 2020; 23(8):1038-1044. PMID32283084.

Resio BJ, Canavan M, Mase V, Dhanasopon AP, Blasberg JD, Boffa DJ. Invasive Staging Procedures Do Not Prevent Nodal Metastases from Being Missed In Stage I Lung Cancer. Ann Thorac Surg. 2020; 110(2):390-397. PMID32283084.

Pathak R, Goldberg SB, Canavan M, Herrin J, Hoag JR, Salazar MC, Papageorge M, Ermer T, Boffa DJ. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. JAMA Oncol. 2020;6(11):1-10. PMID32940636.

Leapman MS, Presley CJ, Zhu W, Soulos PR, Adelson KB, Miksad RA, Boffa DJ, Gross CP. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Netw Open. 2020;3(6):e207205. PMID32511721.

Saphire M, Prsic E, Canavan ME, Wang S, Presley CJ, Davidoff AJ. Patterns of Symptom Management Medication Receipt at End-of-Life Among Medicare Beneficiaries with Lung Cancer. J Pain Symptom Manage. 2020;59(4):767-777. PMID31778783.

Jean RA, Bongiovanni T, Soulos PR, Chiu AS, Herrin J, Kim N, Xu X, Kim AW, Gross CP. Hospital Variation in spending for Lung Cancer Resection in Medicare Beneficiaries. Ann Thorac Surg. 2019;108(6):1710-1716. PMID31400321.

Giri S, Huntington SF. Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer. JAMA Oncol. 2019;5(7):1066. PMID31095252.

Riaz F, Presley CJ, Chiang AC, Longtine JA, Soulos PR, Adelson KB, Herbst RS, Nussbaum NC, Sorg RA, Abernathy AP, Agarwala V, Gross CP. Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer. J Geriatr Oncol. 2019;10(4):669-672. PMID30718180.

Kann BH, Verma V, Stahl JM, Ross R, Dosoretz AP, Shafman TD, Gross CP, Park HS, Yu JB, Decker RH. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma. Radiother Oncol. 2019;134:44-49. PMID31005223.

Jean RA, Chiu AS, Hoag JR, Blasberg JD, Boffa DJ, Detterbeck FC, Kim AW. Identifying Drivers of Multiple Readmissions Following Pulmonary Lobectomy. Ann Thorac Surg. 2019;107(3):947-953. PMID30336117.

Kann BH, Miccio JA, Stahl JM, Ross R, Verma V, Dosoretz AP, Park HS, Shafman TD, Gross CP, Yu JB, Decker RH. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. Radiother Oncol. 2019;132:188-196. PMID30391106.

Thomas DC, Arnold BN, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, Boffa DJ, Kim AW. The Significance of Upfront Knowledge of N2 Disease in Non-small Cell Lung Cancer. World J Surg. 2018;42(1):161-171. PMID28799084.

Arnold BN, Thomas DC, Narayan R, Blasberg JD, Detterbeck FC, Boffa DJ, Kim AW. Robotic-Assisted Lobectomies in the National Cancer Database. J Am Coll Surg. 2018;226(6):1052-1062. PMID29574177.

Jean RA, Chiu AS, Boffa DJ, Detterbeck FC, Blasberg JD, Kim AW. When good operations go bad: The additive effect of comorbidity and postoperative complications on readmission after pulmonary lobectomy. Surgery. 2018;164(2):294-299. PMID29801731.

Jean RA, Chiu AS, Boffa DJ, Detterbeck FC, Kim AW, Blasberg JD. Delayed discharge does not decrease the cost of readmission after pulmonary lobectomy. Surgery. 2018;164(6):1294-1299. PMID30064733.

Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. JAMA. 2018;320(5):469-477. PMID30088010.

Andreano A, Peake MD, Janes SM, Valsecchi MG, Pritchard-Jones K, Hoag JR, Gross CP. The Care and Outcomes of Older Persons with Lung Cancer in England and the United States, 2008-2012. J Thorac Oncol. 2018;13(7):904-914. PMID29727739.

Resio BJ, Chiu AS, Hoag J, Dhanasopon AP, Blasberg JD, Boffa DJ. Primary Salivary Type Lung Cancers in the National Cancer Database. Ann Thorac Surg. 2018;105(6):1633-1639. PMID29486180.

Thomas DC, Arnold BN, Hoag JR, Salazar MC, Boffa DJ, Detterbeck FC, Kim AW, Blasberg JD. Timing and Risk Factors Associated with Venous Thromboembolism Following Lung Cancer Resection. Ann Thorac Surg. 2018;105(5):1469-1475. PMID29501644.

Wang EH, Corso CD, Park HS, Chen AB, Wilson LD, Kim AW, Decker RH, Yu JB. Association Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non-Small Cell Lung Cancer. Am J Clin Oncol. 2018; 41(2):152–158; PMID26523443.

Dhanasopon AP, Salazar MC, Hoag JR, Rosen JE, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Fate of Pneumonectomy Patients Variably Captured by Non-Small Cell Lung Cancer Staging System. Ann Thorac Surg. 2017; 104(6):1829-1836; PMID29074151.

Presley CJ, Soulos PR, Tinetti M, Montori VM, Yu JB, Gross CP. Treatment burden among Medicare beneficiaries with early-stage lung cancer. J Oncol Pract. 2017;13(2):e98-e107. PMID27997301.

Rosen JE, Salazar MC, Dharmarajan K, Kim AW, Detterbeck FC, Boffa DJ. Length of Stay From the Hospital Perspective: Practice of Early Discharge Is Not Associated With Increased Readmission Risk After Lung Cancer Surgery. Ann Surg. 2017;266(2):383-388. PMID27564681.

Salazar MC, Rosen JE, Wang Z, Arnold BN, Thomas DC, Herbst RS, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery. JAMA Oncol. 2017;3(5):610-619. PMID28056112.

Gao SJ, Corso CD, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall. Clin Lung Cancer. 2017;18(2):169-177. PMID27890561.

Thomas DC, Arnold BN, Rosen JE, Salazar MC, Blasberg JD, Detterbeck FC, Boffa DJ, Kim AW. Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery. Lung Cancer. 2017;103:75-81. PMID28024700.

Gao SJ, Corso CD, Wang EH, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(2):314-322. PMID27720827.

Tchouta LN, Park HS, Boffa DJ, Blasberg JD, Detterbeck FC, Kim AW. Hospital volume and outcomes of robot-assisted lobectomies. Chest. 2017;151(2):329-339. PMID27687847.

Jawitz OK, Wang Z, Boffa DJ, Detterbeck FC, Blasberg JD, Kim AW. The differential impact of preoperative comorbidity on perioperative outcomes following thoracoscopic and open lobectomies. Eur J Cardiothorac Surg. 2017;51(1):169-174. PMID27458143.

Harder EM, Park HS, Chen ZJ, Decker RH. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy. Pract Radiat Oncol. 2016;6:e353-e359. PMID27156424.

Stahl JM, Ross R, Harder EM, Mancini BR, Soulos PR, Finkelstein SE, Shafman TD, Dosoretz AP, Evans SB, Husain ZA, Yu JB, Gross CP, Decker RH. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016;96(5):1011-1020. PMID27869080.

Lester-Coll NH, Rutter CE, Bledsoe TJ, Goldberg SB, Decker RH, Yu JB. Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. Int J Radiat Oncol Biol Phys. 2016;95(2):663-72. PMID27055395.

Sandler BJ, Wang Z, Hancock JG, Boffa DJ, Detterbeck FC, Kim AW. Gender, Age, and Comorbidity Status Predict Improved Survival with Adjuvant Chemotherapy Following Lobectomy for Non-small Cell Lung Cancers Larger than 4 cm. Ann Surg Oncol. 2016;23(2):638-45. PMID26474557.

Salazar MC, Rosen JE, Arnold BN, Thomas DC, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Adjuvant Chemotherapy for T3 Non-Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe. J Thorac Oncol. 2016;11(7):1090-100. PMID27013407.

Rosen JE, Keshava HB, Yao X, Kim AW, Detterbeck FC, Boffa DJ. The Natural History of Operable Non-Small Cell Lung Cancer in the National Cancer Database. Ann Thorac Surg. 2016;101(5):1850-5. PMID27041452.

DeLuzio MR, Keshava HB, Wang Z, Boffa DJ, Detterbeck FC, Kim AW. A model for predicting prolonged length of stay in patients undergoing anatomical lung resection: a National Surgical Quality Improvement Program (NSQIP) database study. Interact Cardiovasc Thorac Surg. 2016;23(2):208-15. PMID27073262.

Arnold BN, Thomas DC, Rosen JE, Salazar MC, Blasberg JD, Boffa DJ, Detterbeck FC, Kim AW. Lung Cancer in the Very Young: Treatment and Survival in the National Cancer Data Base. J Thorac Oncol. 2016 Jul;11(7):1121-31. PMID27103511.

Jean RA, DeLuzio MR, Kraev AI, Wang G, Boffa DJ, Detterbeck FC, Wang Z, Kim AW. Analyzing Risk Factors for Morbidity and Mortality after Lung Resection for Lung Cancer Using the NSQIP Database. J Am Coll Surg. 2016;222(6):992-1000. PMID27118714.

Rosen JE, Salazar MC, Wang Z, Yu JB, Decker RH, Kim AW, Detterbeck FC, Boffa DJ. Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer. J Thorac Cardiovasc Surg. 2016;152(1):44-54. PMID27131846.

Liu J, Hancock JG, Moreno AC, Wang Z, Boffa DJ, Detterbeck FC, Kim AW. Evaluating the fate of patients who undergo resections of very large, node-negative lung cancers using the National Cancer DataBase. EurJ Card iothorac Surg. 2016;49(2):596-601. PMID25890936.

Erb CT, Su KW, Soulos PR, Tanoue LT, Gross CP. Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population. Lung Cancer. 2016;99:200-7. PMID27565940.

Presley CJ, Gross CP, Lilenbaum RC. Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient. J Clin Oncol. 2016;34(13):1438-42. PMID27001591.

Park HS, Decker RH, Wilson LD, Yu JB. Prophylactic Cranial Irradiation for Patients With Locally Advanced Non-Small-Cell Lung Cancer at High Risk for Brain Metastases. Clin Lung Cancer. 2015;16(4):292-7. PMID25499149.

Yu JB, Soulos PR, Cramer LD, Decker RH, Kim AW, Gross CP. The Comparative Effectiveness of Surgery and Radiosurgery for Stage I Non-Small Cell Lung Cancer. Cancer. 2015;121(14):2341-9. PMID25847699.

Wang EH, Rutter CE, Corso CD, Decker RH, Wilson LD, Kim AW, Yu JB, Park HS. Patients Selected for Definitive Concurrent Chemoradiation at High-volume Facilities Achieve Improved Survival in Stage III Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015;10(6):937-43. PMID25738221.

Corso CD, Park HS, Kim AW, Yu JB, Husain Z, Decker RH. Racial disparities in the use of SBRT for treating early-stage lung cancer. Lung Cancer. 2015;89(2):133-8. PMID26051446.

Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, Wilson LD, Decker RH, Yu JB. Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer. J Clin Oncol. 2015;33(25):2727-34. PMID26101240.

Corso CD, Rutter CE, Park HS, Lester-Coll NH, Kim AW, Wilson LD, Husain ZA, Lilenbaum RC, Yu JB, Decker RH. Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer. J Clin Oncol. 2015;33(36):4240-6. PMID26481366.

Park HS, Decker RH, Wilson LD, Yu JB. Prophylactic Cranial Irradiation for Patients With Locally Advanced Non-Small-Cell Lung Cancer at High Risk for Brain Metastases. Clin Lung Cancer. 2015;16(4):292-7. PMID25499149.


Meckstroth S, Wang R, Ma X, Podoltsev N. Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. Clin Lymphoma Myeloma Leuk. 2021;21(6):e551-e558. PMID33648884.

Mun S, Wang R, Ma X, Ananth P. Sociodemographic and hospital-based predictors of intense end-of-life care among children, adolescents, and young adults with hematologic malignancies. Cancer. 2021;127(20):3817-3824. PMID34185881.

Wang X, Zeidan AM, Wang R, Bewersdorf JP, Zhang C, Podoltsev NA, Huntington SF, Gore SD, Ma X. Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leuk Lymphoma. 2021;62(1):2438-2447. PMID33899659.

Bewersdorf JP, Patel KK, Huntington SF, Zeidan AM. Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia. Blood Adv. 2021;5(22):4686–4690. PMID34525174.

Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. J Clin Oncol. 2021;39(10):1119–1128. PMID33411586.

Patel KK, Zeidan AM, Shallis RM, Prebet T, Podoltsev N, Huntington SF. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Adv. 2021;5(4):994–1002. PMID33591323.

Podoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa R, Ma X. Lifestyle Factors and Risk of Myeloproliferative Neoplasms in the NIH-AARP Diet and Health Study. Int J Cancer. 2020;147(4):948-957. PMID31904114.

Podoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa RA, Ma X. Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort. Cancer Epidemiol Biomarkers Prev. 2020;29(11):2343-2350. PMID32868318.

Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood.136(17):1946-1955. PMID32518952.

Giri S, Huntington SF, Wang R, Zeidan AM, Podoltsev N, Gore SF, Ma X, Gross CP, Davidoff AJ, Neparidze N. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Adv. 2020;4(10):2245-2253. PMID32442299.

Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Adv. 2020;4(8):1615-1623. PMID32311013.

Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Rev. 2020;42:100706. PMID32517877.

Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leuk Lymphoma. 2020;61(2):397-408. PMID31570040.

Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Adv. 2020;4(10):2192-2201. PMID32433746.

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The Impact of Hydroxyurea on Survival and Risk of Thrombosis among Older Patients with Essential Thrombocythemia. J Natl Compr Canc Netw. 2019;17(3):211-219. PMID30865915.

Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1-15. PMID30314642.

Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70-87. PMID31101526.

Huntington SF, Zhu W, Hoag JR, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma. JNCI Cancer Spectr. 2019;3(2):pkz030. PMID31360905.

Huntington SF, Hoag JR, Wang R, Zeidan AM, Giri S, Gore SD, Ma X, Gross CP, Davidoff AJ. Physician experience and risk of rituximab discontinuation in older adults with non-Hodgkin’s lymphoma. J Natl Compr Canc Netw. 2019;17(10):1194-1202. PMID31590152.

Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore SD, Neparidze N, Ma X, Gross CP, Davidoff AJ, Huntington SF. Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States. Cancer. 2019;125(22):4084-4095. PMID31381151.

Zeidan AM, Podoltsev NA, Wang X, Bewersdorf JP, Shallis RM, Huntington SF, Gore SD, Davidoff AJ, Ma X, Wang R. Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population-level analysis. Cancer. 2019;125(23):4241-4251. PMID31483484.

Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leuk Lymphoma. 2019;60(13):3181-3187. PMID31170846.

Bewersdorf JP, Shallis RM, Wang R, Huntington SF, Perreault S, Ma X, Zeidan AM. Healthcare expenses for treatment of acute myeloid leukemia. Expert Rev Hematol. 2019;12(8):641-650. PMID31159602.

Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131(7):818-821. PMID29259002.

Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer J. 2018;8(6):55. PMID29891916.

Olszewski AJ, Dusetzina SB, Trivedi AN, Davidoff AJ. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. J Clin Oncol. 2018;36(28):2879-2886. PMID30113885.

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Adv. 2018;2(20):2681-2690. PMID30333100.

Huntington SF, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Oncologist Volume and Outcomes in Older Adults Diagnosed With Diffuse Large B Cell Lymphoma. Cancer. 2018;124(21):4211-4220. PMID30216436.

Zeidan AM, Wang R, Gross CP, Gore SD, Huntington SF, Prebet T, Abel GA, Davidoff AJ, Ma X. Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. Leuk Lymphoma. 2017;58(4):982-985. PMID27558206.

Wang R, Zeidan A, Soulos PR, Yu JB, Davidoff AJ, Gore SD, Gross CP, and Ma X. Myelodysplastic syndromes and acute myeloid leukemia in prostate cancer patients after radiotherapy: a population-based study. Prostate. 2017;77(5):437-445. PMID27868212.

Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF. Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer. 2017;123(19):3763-3771. PMID28640385.

Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev N, Huntington SF, Gore SD, Davidoff AJ. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic Leukemia in the United States: A large population-based study. Cancer. 2017;123(19):3754-3762. PMID28621841.

Wang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, Gore SD, Ma X. Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. J Clin Oncol. 2017;35(30):3417-3424. PMID28783450.

Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study. Leuk Lymphoma. 2020;61(5):1178-1187. PMID31878809.

Zeidan AM, Wang R, Davidoff AJ, Ma S, Zhao Y, Gore SD, Gross CP, Ma X. Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes. Cancer. 2016;122(10):1598-607. PMID26970288.

Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016;175(5):829-840. PMID27650975.


Lee V, Jairam V, Yu JB, Park HS. Nationwide patterns of hemorrhagic stroke among patients hospitalized with brain metastases: influence of primary cancer diagnosis and anticoagulation. Sci Rep. 2020;10(1):10084. PMID32572113.

Yeboa DN, Rutter CE, Park HS, Lester-Coll NH, Corso CD, Mancini BR, Bindra RS, Contessa J, Yu JB. Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas. Radiother Oncol. 2017; 125(2):258-265; PMID29054377.

Kann BH, Park HS, Johnson SB, Chiang VL, Yu JB. Radiosurgery for Brain Metastases: Changing Practice Patterns and Disparities in the United States. J Natl Compr Canc Netw. 2017;15(12):1494-1502. PMID29223987.

Park HS, Wang EH, Rutter CE, Corso CD, Chiang VL, Yu JB. Changing practice patterns of Gamma Knife versus linear accelerator-based stereotactic radiosurgery for brain metastases in the US. J Neurosurg. 2016;124(4):1018-24. PMID26473783.

Lester-Coll NH, Dosoretz AP, Hayman JA, Yu JB. Health State Utilities for Patients with Brain Metastases. Cureus. 2016;8(7):e667. PMID27551647.

Kole AJ, Park HS, Yeboa DN, Rutter CE, Corso CD, Aneja S, Lester-Coll NH, Mancini BR, Knisely JP, Yu JB. Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme. Cancer. 2016;122(15):2364-70. PMID27172136.

Lester-Coll NH, Dosoretz AP, Magnuson WJ, Laurans MS, Chiang VL, Yu JB. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases. J Neurosurg. 2016;125(Suppl 1):18-25. PMID27903191.


Nguyen KA, Nolte AC, Alimi O, Hsiang W, Lu AJ, Ghabili K, Syed JS, Suarez-Sarmiento A, Perecman AJ, Shuch B, Leapman MS. Determinants of Active Surveillance in Patients With Small Renal Masses. Urology. 2019;123:167-173. PMID30059717.

Kim SP, Gross CP, Meropol N, Kutikov A, Smaldone MC, Shah ND, Yu JB, Psutka S, Kiechle J, Abouassaly R. National treatment trends among older patients with T1-localized renal cell carcinoma. Urol Oncol. 2017;35(3):113.e15-113.e21. PMID27839926.


Gupta A, Long JB, Chen J, Gross CP, Feldman DR, Steingart RM. Risk of Vascular Toxicity with Platinum Based Chemotherapy in Elderly Patients with Bladder Cancer. J Urol. 2016;195(1):33-40. PMID26341576.

Wang EH, Yu JB. Chemoradiation Therapy for Organ Preservation in Localized Male Urethral Carcinoma. Oncology (Williston Park). 2016;30(6):520-3. PMID27306708.


Kho RM, Desai VB, Schwartz PE, Wright JD, Gross CP, Hutchison LM, Boscoe FP, Lin H, Xu X. Endometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma. J Minim Invasive Gynecol. 2021;29(1):119-127. PMID34265441.

Xu X, Desai VB, Wright JD, Lin H, Schwartz PE, Gross CP. Hospital Variation in Responses to Safety Warnings about Power Morcellation in Hysterectomy. Am J Obstet Gynecol. 2021;224(6):589.e1-589.e13. PMID33359176..

Desai VB, Wright JD, Gross CP, Lin H, Boscoe FP, Schwartz PE, Xu X. Risk of unexpected uterine Cancer in women undergoing myomectomy: A population-based study. Eur J Obstet Gynecol Reprod Biol. 2019;238:188-190. PMID31103353.

Desai VB, Wright JD, Lin H, Gross CP, Sallah YH, Schwartz PE, Xu X. Laparoscopic Hysterectomy Route, Resource Use, and Outcomes: Change After Power Morcellation Warning. Obstet Gynecol. 2019;134(2):227-238. PMID31348209.

Xu X, Lin H, Wright JD, Gross CP, Boscoe FP, Hutchison LM, Schwartz PE, Desai VB. Association between power morcellation and mortality in women with unexpected uterine cancer undergoing hysterectomy or myomectomy. J Clin Oncol. 2019 Dec 10;37(35):3412-3424. PMID31518176.

Desai VB, Wright JD, Gross CP, Lin H, Boscoe FP, Hutchison LM, Schwartz PE, Xu X. Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy. Am J Obstet Gynecol. 2019;221(1):39.e1-39.e14. PMID30853364.

Yang DX, Soulos PR, Davis B, Gross CP, Yu JB. Impact of widespread cervical cancer screening: number of cancers prevented and changes in race-specific incidence. Am J Clin Oncol. 2018; 41(3):289-294. PMID26808257.

Desai VB, Wright JD, Schwartz PE, Jorgensen EM, Fan L, Litkouhi B, Lin H, Gross CP, Xu X. Occult Gynecologic Cancer in Women Undergoing Hysterectomy or Myomectomy for Benign Indications. Obstet Gynecol. 2018;131(4):642-651. PMID29528920.


Pathak R, Canavan ME, Walters S, Salazar MC, Boffa DJ. Chemoradiation as a nonsurgical treatment option for early-stage esophageal cancers: a retrospective cohort study. J Thorac Dis. 2021;13(1):140–148. PMID33569194.

Sathe TS, Resio BJ, Hoag JR, Monsalve AF, Pathak R, Blasberg JD, Mase V Jr, Dhanasopon A, Boffa DJ. Surgically-Managed Signet Ring Cell Esophageal Carcinomas in the National Cancer Database. Ann Thorac Surg. 2020;109(6):1656-1662. PMID32109449.


Cheng E, Hung P, Wang SY. Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study. J Natl Compr Canc Netw. 2020;18(6):729-736. PMID32502978..

Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLoS One. 2020;15(10):e0240542. PMID33052942.

Cheng E, Hung P, Wang SY. Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study. J Natl Compr Canc Netw. 2020;18(6):729-736. PMID32502978.


Hsiang W, Han X, Jemal A, Nguyen KA, Shuch B, Park H, Yu JB, Gross CP, Davidoff AJ, Leapman MS. The association between the Affordable Care Act and insurance status, stage and treatment in patients with testicular cancer. Urology Practice. 2020;7(4):252-8.


Ananth P, Mun S, Reffat N, Li R, Sedghi T, Bilodeau M, Snaman J, Gross CP, Ma X, Wolfe J. A Stakeholder-Driven Qualitative Study to Define High Quality End-of-Life Care for Children with Cancer. J Pain Symptom Manage. 2021;62(3):492-502. PMID33556497.

Salazar MC, Kaminski MF, Canavan ME, Maduka RC, Li AX, Ermer T, Boffa DJ. Baseline Evaluation of Cancer Mortality in US States that Expanded Medicaid vs Nonexpansion States. JAMA Oncol. 2021;7(9):1394-1395. PMID34292299.

Ananth P. Reenvisioning End-of-Life Care Quality Measurement for Adolescents and Young Adults With Cancer-Novel Patient-Centered Indicators and Approaches. JAMA Netw Open. 2021;4(8): e2122323. PMID34424309.

Sheinson DM, Wong WB, Flores C, Ogale, S, Gross CP. Association Between Medicare's National Coverage Determination and Utilization of Next-Generation Sequencing. JCO Oncol Pract. 2021;17(11):e1774–e1784. PMID34043456.

Talcott WJ, Yu JB, Gross CP,Park HS. Social Connectedness Among Medicare Beneficiaries Following the Onset of the COVID-19 Pandemic. JAMA Intern Med. 2021;181(9):1245–1248. PMID34047760.

Lopez L 3rd, Dhodapkar M, Gross CP. US Nonprofit Hospitals' Community Health Needs Assessments and Implementation Strategies in the Era of the Patient Protection and Affordable Care Act. JAMA Newt Open. 2021;4(8):e2122237. PMID34427683.

Hsu SH, Chang SH, Gross CP, Wang SY. Relative risks of COVID-19 fatality between the first and second waves of the pandemic in Ontario, Canada. Int J Infect Dis. 2021;109:189–191. PMID34216734.

Adamson BJS, Cohen AB, Gross CP, Estévez M, Magee K, Williams E, Meropol NJ, Davidoff AJ. ACA Medicaid expansion association with racial disparity reductions in timely cancer treatment. Am J Manag Care. 2021;27(7):274–281. PMID34314116.

Varma T, Wallach JD, Miller JE, Schnabel D, Skydel JJ, Zhang AD, Dinan MA, Ross JS, Gross CP. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. JAMA Newt Open. 2021;4(4):e217063. PMID33877309.

Shi K, Hung P, Wang SY. Associations Among Health Literacy, End-of-Life Care Expenditures, and Rurality. J Rural Health. 2021;37(3):517–525. PMID32894605.

Mahal AR, Cramer LD, Wang EH, Wang S, Davidoff AJ, Gross CP, Yu JB. Did quality of life for older cancer survivors improve with the turn of the century in the United States? J Geriatr Oncol. 2021;12(1):102–105. PMID32535014.

Cheng E, Soulos PR, Irwin ML, Cespedes Feliciano EM, Presley CJ, Fuchs CS, Meyerhardt JA, Gross CP. Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers. JAMA Newt Open. 2021;4(12):e2139593. PMID34919133.

Feder SL, Canavan ME, Wang SY, Kent EE, Kapo J, Presley CJ, Ross J, Davidoff AJ. Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions. J Palliat Med. 2021;24(2):195-204 PMID32673139.

Resio BJ, Gonsalves L, Canavan M, Mueller L, Phillips C, Sathe T, Swett K, Boffa DJ. Where the Other Half Dies: Analysis of Mortalities Occurring More Than 30 Days After Complex Cancer Surgery. Ann Surg Oncol. 2021;28(3):1278-1286. PMID32885398.

Jairam V, Yang DX, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS. Temporal Trends in Opioid Prescribing Patterns Among Oncologists in the Medicare Population. J Natl Cancer Inst. 2021;113(3):274-281. PMID32785685.

Ananth P, Revette A, Reed-Weston A, Das P, Wolfe J. Parent and patient perceptions of medical marijuana in the childhood cancer context. Pediatr Blood Cancer. 2021;68(4):e28830. PMID33258215.

Nolte AC, Nguyen KA, Perecman A, Katz MS, Kenney PA, Cooperberg MR, Gross CP, Leapman MS. Association Between Twitter Reception at a National Urology Conference and Future Publication Status. Eur Urol Focus. 2021;7(1):214-220. PMID31103604.

Prozora S, Shabanova V, Ananth P, Pashankar F, Kupfer GM, Massaro SA, Davidoff AJ. Patterns of medication use at end of life by pediatric inpatients with cancer. Pediatr Blood Cancer. 2021;68(5):e28837. PMID33306281.

Puglisi L, Halberstam AA, Aminawung J, Gallagher C, Gonsalves L, Schulman-Green D, Lin HJ, Metha R, Mun S, Oladeru OT, Gross C, Wang EA. Incarceration and Cancer-Related Outcomes (ICRO) study protocol: using a mixed-methods approach to investigate the role of incarceration on cancer incidence, mortality and quality of care. BMJ Open. 2021;11(5):e048863. PMID34035109.

Presley CJ, Canavan M, Wang SY, Feder SL, Kapo J, Saphire ML, Sheinfeld E, Kent EE, Davidoff AJ. Severe functional limitation due to pain & emotional distress and subsequent receipt of prescription medications among older adults with cancer. J Geriatr Oncol. 2020;11(6):960-968. PMID32169548.

Salazar MC, Canavan ME, Walters SL, Herrin J, Schwartz JL, Leapman M, Boffa DJ. Evaluation of Cancer Care After Medicaid Expansion Under the Affordable Care Act. JAMA Netw Open. 2020; 3(9):e2017544. PMID32990734.

Bongiovanni T, Kim SP, Kim A, Killelea B, Gross C. Is there variation in private payor payments to cancer surgeons? A cross-sectional study in the USA. BMJ Open. 2020;10(10):e035438. PMID33020076.

Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, Adamson BJ, Shaw P, Parikh RB, Mamtani R, Gross CP. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncol Pract. 2020;16(11):e1355-e1370. PMID32678688.

Gross CP, Essien UR, Pasha S, Gross JR, Wang SY, Nunez-Smith M. Racial and Ethnic Disparities in Population-Level Covid-19 Mortality. J Gen Intern Med. 2020;35(10):3097-3099. PMID32754782.

Mahal AR, Cramer LD, Wang EH, Wang SY, Davidoff AJ, Gross CP, Yu JB. Did quality of life for older cancer survivors improve with the turn of the century in the United States? J Geriatr Oncol. 2020; 12(1):102-105. PMID32535014.

Papageorge MV, Resio BJ, Monsalve AF, Canavan M, Pathak R, Mase VJ, Dhanasopon AP, Hoag JR,Blasberg JD, Boffa DJ. Navigating by Stars: Using CMS Star Ratings to Choose Hospitals for Complex Cancer Surgery. JNCI Cancer Spectr. 2020;4(5):pkaa059. PMID33134834.

Jairam V, Yang DX, Yu JB, Park HS. Emergency Department Visits for Opioid Overdoses Among Patients With Cancer. J Natl Cancer Inst. 2020; PMID31845985.

Jairam V, Lee V, Yu JB, Park HS. Nationwide Patterns of Pathologic Fractures Among Patients Hospitalized With Bone Metastases. Am J Clin Oncol. 2020;43(10):720-726. PMID32694296.

Jairam C, Yang DX, Verma V, Yu JB, Park HS. National Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States. JAMA Netw Open. 2020;3(8):e2013605. PMID32804217.

Huntington SF, Davidoff AJ, Gross CP. Precision medicine in oncology II: Economics of targeted agents and Immuno-Oncology drugs. J Clin Oncol. 2020;38(4):351-358. PMID31804866.

Boffa DJ, Mallin K, Herrin J, Resio B, Salazar MC, Palis B, Facktor M, McCabe R, Nelson H, Shulman LN. Survival After Cancer Treatment at Top-Ranked US Cancer Hospitals vs Affiliates of Top-Ranked Cancer Hospitals. JAMA Netw Open. 2020;3(5):e203942. PMID32453382.

Davidoff AJ, Canavan ME, Feder S, Wang S, Sheinfeld E, Kent EE, Kapo J, Presley CJ. Patterns of pain medication use associated with reported pain interference in older adults with and without cancer. Support Care Cancer. 2020;28(7):3061-3072. PMID31637515.

Puglisi LB, Winkelman TNA, Gross CP, Wang EA. Cancer Prevalence Among Adults with Criminal Justice Involvement from a National Survey. J Gen Intern Med. 2020;35(3):967-968. PMID31321602.

Presley CJ, Han L, Leo-Summers L, Hurria A, Gross CP, Davidoff AJ, Allore HG, Gill TM. Functional trajectories before and after a new cancer diagnosis among community-dwelling older adults. J Geriatr Oncol. 2019;10(1):60-67. PMID29937422.

Hsu SH, Hung P, Wang SY. Factors Associated with Hospices’ Non-Participation in Medicare’s Hospice Compare Public Reporting Program. Med Care. 2019;57(1):28-35. PMID30489545.

Herrin J, Soulos PR, Xu X, Gross CP, Pollack CE. To develop an empiric approach for evaluating the performance of physician peer groups based on patient-sharing in administrative claims data. Health Serv Res. 2019;54(1):44-51. PMID30488484.

Wang SY, Hsu SH, Aldridge MD, Cherlin E, Bradley E. Racial Differences in Health Care Transitions and Hospice Use at the End of Life. J Palliat Med. 2019;22(6):619-627. PMID30615546.

Chiu AS, Resio B, Hoag JR, Monsalve AF, Blasberg JD, Brown L, Omar A, White MA, Boffa DJ. Why Travel for Complex Cancer Surgery? Americans React to 'Brand-Sharing' Between Specialty Cancer Hospitals and Their Affiliates. Ann Surg Oncol. 2019;6(3):732-738. PMID30311158.

Chiu AS, Arnold BN, Hoag JR, Herrin J, Kim CH, Salazar MC, Monsalve AF, Jean RA, Blasberg JD, Detterbeck FC, Gross CP, Boffa DJ. Quality Versus Quantity: The Potential Impact of Public Reporting of Hospital Safety for Complex Cancer Surgery. Ann Surg. 2019;270(2):281-287. PMID29697446.

Jairam V, Lee V, Park HS, Thomas CR Jr, Melnick ER, Gross CP, Presley CJ, Adelson KB, Yu JB. Treatment-Related Complications of Systemic Therapy and Radiotherapy. JAMA Oncol. 2019;5(7):1028-1035. PMID30946433.

Resio BJ, Hoag JR, Chiu AS, Monsalve A, Sathe T, Xu X, Boffa DJ. Variations in Surgical Safety According to Affiliation Status With a Top-Ranked Cancer Hospital. JAMA Oncol. 2019;5(9):1359-1362. PMID31294746.

Johnson SB, Park HS, Gross CP, Yu JB. Use of Alternative Medicine for Cancer and Its Impact on Survival. J Natl Cancer Inst. 2018; 110(1). PMID28922780.

Davidoff AJ, Guy GP Jr, Hu X, Gonzales F, Han X, Zheng Z, Parsons H, Ekwueme DU, Jemal A. Changes in Health Insurance Coverage Associated With the Affordable Care Act Among Adults With and Without a Cancer History: Population-based National Estimates. Med Care. 2018; 56(3):220-227. PMID29438192.

Maroongroge S, Yu JB. Medicare Cancer Screening in the Context of Clinical Guidelines: 2000 to 2012. Am J Clin Oncol. 2018;41(4):339-347. PMID26886947.

O’Connor JM, Fessele KL, Steiner J, Seidl-Rathkopf K, Carson KR, Nussbaum NC, Yin ES, Adelson KB, Presley CJ, Chiang AC, Ross JS, Abernethy AP, Gross CP. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncol. 2018; 4(8):e180798. PMID29800974.

Wang SY, Hsu SH, Huang S, Doan KC, Gross CP, Ma X. Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res. 2018;53(6):4291-4309. PMID29951996.

Johnson SB, Park HS, Gross CP, Yu JB. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. JAMA Oncol. 2018;4(10):1375-1381. PMID30027204.

O’Connor JM, Seidl-Rathkopf K, Torres AZ, You P, Carson KR, Ross JS, Gross CP. Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors. Oncologist. 2018;23(11):1388-1390. PMID30012876.

Chiu AS, Resio B, Hoag JR, Monsalve AF, Blasberg JD, White MA, Boffa DJ. US Public Perceptions About Cancer Care Provided by Smaller Hospitals Associated With Large Hospitals Recognized for Specializing in Cancer Care. JAMA Oncol. 2018;4(7):1008-1009. PMID29852033.

Kadan-Lottick NS, Ross WL, Mitchell HR, Rotatori J, Gross CP, Ma X. Randomized Trial of the Impact of Empowering Childhood Cancer Survivors With Survivorship Care Plans. J Natl Cancer Inst. 2018;110(12):1352-1359. PMID29771337.

O'Connor JM, Sedghi T, Dhodapkar M, Kane MJ, Gross CP. Factors Associated With Cancer Disparities Among Low-, Medium-, and High-Income US Counties. JAMA Netw Open. 2018;1(6):e183146. PMID30646225.

Encinosa W, Davidoff AJ. Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations. JAMA Oncol. 2017;3(3):320-326. PMID27632203.

Wang S, Hsu SH, Huang S, Soulos PR, Gross CP. Longer Periods Of Hospice Service Associated With Lower End-Of-Life Spending In Regions With High Expenditures. Health Aff. 2017;36(2):328-336. PMID28167723.

Wang SY, Dang W, Aldridge MD, Canavan M, Cherlin E, Bradley E. Associations of Hospice Disenrollment and Hospitalization With Continuous Home Care Provision. Med Care. 2017;55(9):848-855. PMID28692573.

Wang SY, Aldridge MD, Gross CP, Canavan M, Cherlin E, Bradley E. End-of-Life Care Transition Patterns of Medicare Beneficiaries. J Am Geriatr Soc. 2017;65(7):1406-1413. PMID28369785.

Jairam V, Yu JB. Examination of Industry Payments to Radiation Oncologists in 2014 Using the Centers for Medicare and Medicaid Services Open Payments Database. Int J Radiat Oncol Biol Phys. 2016;94(1):19-26. PMID26547386.

Wang SY, Aldridge MD, Gross CP, Canavan M, Cherlin E, Johnson-Hurzeler R, Bradley E. Transitions Between Healthcare Settings of Hospice Enrollees at the End of Life. J Am Geriatr Soc. 2016;64(2):314-22. PMID26889841.

Wang SY, Hall J, Pollack CE, Adelson K, Bradley EH, Long JB, Gross CP. Trends in end-of-life cancer care in the Medicare program. J Geriatr Oncol. 2016;7(2):116-25. PMID26783015.

Wang SY, Aldridge MD, Gross CP, Canavan M, Cherlin E, Johnson-Hurzeler R, Bradley E. End-of-Life Care Intensity and Hospice Use: A Regional-level Analysis. Med Care. 2016;54(7):672-8. PMID27111747.

Wang SY, Hsu SH, Gross CP, Sanft T, Davidoff AJ, Ma X, Yu JB. Association between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis. Value Health. 2016;19(5):631-8. PMID27565280.

Wang SY, Hall J, Pollack CE, Adelson K, Davidoff AJ, Long JB, Gross CP. Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures. J Natl Compr Canc Netw. 2016;14(8):1001-8. PMID27496116.

Wang SY, Aldridge MD, Canavan M, Cherlin E, Bradley E. Continuous home care reduces hospice disenrollment and hospitalization after hospice enrollment. J Pain Symptom Manage. 2016;52(6):813-821. PMID27697564.

Rutter CE, Yu JB, Wilson LD, Park HS. Assessment of national practice for palliative radiation therapy for bone metastases suggests marked underutilization of single-fraction regimens in the United States. Int J Radiat Oncol Biol Phys. 2015;91(3):548-55. PMID25542310.

Wang SY, Aldridge MD, Gross CP, Canavan M, Cherlin E, Johnson-Hurzeler R, Bradley E. Geographic Variation of Hospice Use Patterns at the End of Life. J Palliat Med. 2015;18(9):771-80. PMID26172615.


Dinan MA, Greenup RA. Challenges in Predicting Future Costs for Metastatic Breast Cancer. JNCI Cancer Spectrum. 2021;5(4):pkab064. PMID34409256.

Park HS. Leveraging Surgical Case Volume in Improving Cancer Care Outcomes: Where Do We Go From Here? J Natl Compr Canc Netw. 2021;19(5):577–579. PMID34030129.

Salazar MC, Gross CP. Improving Surgical Cancer Care: A Rising Tide May Lift All Boats, Yet Inequity Persists. JAMA Netw Open. 2020;3(12):e2027809. PMID33270119.

Richman IB, Gross CP. New Breast Cancer Screening Technologies in Older Women-Is It Time to Pump the Brakes? JAMA Intern Med. 2019;79(3):289-290. PMID30640376.

Lehman R, Gross CP. An International Perspective on Drugs for Cancer: The Best of Times, the Worst of Times. JAMA Intern Med. 2019;179(7):913-914. PMID31135827.

Gross CP, Gluck AR. Soaring Cost of Cancer Treatment: Moving Beyond Sticker Shock. J Clin Oncol. 2018;36(4):305-307. PMID29236571.

Zeidan AM, Gore SD, Davidoff AJ. US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box. J Clin Oncol. 2017;35(28):3264. PMID28787256.

Gross CP, Emanuel EJ. A Call for Value in Cancer Research. JAMA Oncol. 2016;2(1):11-2. PMID26447464.

Neugut AI, Gross CP. Targeting the Cancer Moonshot. JAMA Oncol. 2016;2(4):421-2 . PMID26940477.

Huntington SF, Gross CP. Negative Studies in Cancer Research: Why the Negativity? JAMA Oncol. 2016;2(7):865-6. PMID26967116.

Huntington SF, Davidoff AJ. High-Cost, High-Value Oral Specialty Drugs: More Evidence on the Impact of Cost Sharing in Medicare Part D. J Clin Oncol. 2016;34(36):4307-4309. PMID27998230.

Howard DH, Gross CP. Producing Evidence to Reduce Low-Value Care. JAMA Intern Med. 2015;175(12):1893-4. PMID26457957.

Gross CP. Cancer screening in older persons: A new age of wonder. JAMA Intern Med. 2014;174(10):1565-7. PMID25133660.